|
US2007232654A1
|
|
Novel Compounds and Compositions as Cathepsin Inhibitors
|
|
WO2006086609A2
|
|
Inhibitors of tryptase
|
|
WO2006069096A1
|
|
Silanol derivatives as inhibitors of histone deacetylase
|
|
WO2006066183A2
|
|
Novel saframycin analogs as therapeutic agents
|
|
WO2006042103A2
|
|
Reversible inhibitors of cathepsin b
|
|
WO2006044133A1
|
|
Active ketone inhibitors of tryptase
|
|
WO2006034006A1
|
|
Polymorphs of the cysteine protease inhibitor n- (1-cyanocyclopropyl)-3-cyclopropylmethansulfonyl-2 (r) - (2,2,2-trifluoro-1 (s) - (4-fluorophenyl) ethylamino) propionamide
|
|
WO2005121102A2
|
|
Factor viia inhibitor
|
|
WO2005118584A2
|
|
Saframycin analogs as therapeutic agents in the treatment of cancer
|
|
WO2005097103A2
|
|
Diabetes and metabolic syndrome therapy utilizing cathepsin b inhibitors
|
|
US2007105892A1
|
|
Amidino compounds as cysteine protease inhibitors
|
|
US2007141059A1
|
|
Use of cathepsin s inhibitors for treating an immune response caused by administration of a small molecule therapeutic or biologic
|
|
CN1809530A
|
|
Haloalkyl containing compounds as cysteine protease inhibitors
|
|
EP1656348A1
|
|
Acetylene derivatives as inhibitors of histone deacetylase
|
|
ZA200507751B
|
|
Novel hydroxamates as therapeutic agents
|
|
AU2004201071A1
|
|
Amine Derivatives as Protease Inhibitors
|
|
WO2004062661A1
|
|
2-‘5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl!- carboxylic acid derivatives as factor viia inhibitors
|
|
AU2003282804A1
|
|
3-(3,5-disubstituted-4-hydroxyphenyl)propionamide derivatives as cathepsin b inhibitors
|
|
AU2003249713A1
|
|
3,4-dihydroisoquinolin-1-one derivatives as inducers of apoptosis
|
|
AU2003256305A1
|
|
Peptidic compounds as cysteine protease inhibitors
|
